Kimelman & Baird LLC Sells 440 Shares of Eli Lilly and Company $LLY

Kimelman & Baird LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 1.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,283 shares of the company’s stock after selling 440 shares during the quarter. Eli Lilly and Company accounts for approximately 2.8% of Kimelman & Baird LLC’s investment portfolio, making the stock its 15th biggest position. Kimelman & Baird LLC’s holdings in Eli Lilly and Company were worth $34,520,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Covestor Ltd lifted its stake in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $242,000. Finally, TCW Group Inc. grew its stake in shares of Eli Lilly and Company by 12.8% during the first quarter. TCW Group Inc. now owns 14,203 shares of the company’s stock worth $11,730,000 after buying an additional 1,614 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.8%

NYSE LLY opened at $1,067.68 on Tuesday. The firm has a market capitalization of $1.01 trillion, a PE ratio of 69.78, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The business’s 50-day moving average price is $862.28 and its two-hundred day moving average price is $790.04. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,075.72.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 53.9% compared to the same quarter last year. During the same period last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LLY. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. BMO Capital Markets increased their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Berenberg Bank reissued a “hold” rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.